Inhibitors of the GTPase KRAS G12C in cancer: a patent review (2019-2021).

inhibitors will undoubtedly enrich our understanding of KRAS biology and KRAS-targeted therapy, which will shed light on the development of inhibitors targeting other KRAS mutations.